Medizinische Hochschule Hannover Trials

Medizinische Hochschule Hannover	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Hollebecque, Antoine

SGNB6A-001, NCT04389632: A Study of SGN-B6A in Advanced Solid Tumors

Recruiting

824

Europe, US

sigvotatug vedotin, SGN-B6A, pembrolizumab, Keytruda, cisplatin, carboplatin

Seagen Inc.

Carcinoma, Non-Small Cell Lung, Squamous Cell Carcinoma of Head and Neck, HER2 Negative Breast Neoplasms, Esophageal Squamous Cell Carcinoma, Esophageal Adenocarcinoma, Gastroesophageal Junction Adenocarcinoma, Ovarian Neoplasms, Cutaneous Squamous Cell Cancer, Exocrine Pancreatic Adenocarcinoma, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Stomach Neoplasms

11/26

10/28

STEREOLIVER, NCT03408665: Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer

Active, not recruiting

N/A

280

Europe

SBRT

Centre Oscar Lambret, Canceropôle Nord Ouest

Liver Cancer, Liver Metastases

12/26

12/27

NCT04935853: Prognostic and Predictive Markers of Response to Treatment in Patients With Bile Duct Cancer: ACABi PRONOBIL Study

Recruiting

N/A

1350

Europe

GERCOR - Multidisciplinary Oncology Cooperative Group

Biliary Tract Cancer

06/30

06/40

Mosnier, Isabelle

NCT04591093: Auditory Performances With Different Stimulation Depths in Cochlear Implanted Subjects Using a Fine Structure Strategy

Recruiting

N/A

Europe

FineHearing Strategy with 10 more apical electrodes or with 10 more basal electrodes activated

MED-EL Elektromedizinische Geräte GesmbH

Sensorineural Hearing Loss, Bilateral

12/24

DETECT, NCT06424262: Performance and Hearing-related Outcomes in Adults Implanted With the CI622D Dexamethasone-eluting Cochlear Implant Compared to Those Implanted With a Standard Cochlear Implant (CI622)

Not yet recruiting

N/A

Europe, RoW

CI622D, CI622

Cochlear, QbD Clinical, Avania

Hearing Loss, Bilateral Sensorineural, Hearing Loss, Sensorineural, Hearing Loss, Bilateral, Hearing Loss, Cochlear

12/25

05/26

EffICAtt, NCT04733950: Cochlear Implanted Listening Effort and Hearing Attention

Recruiting

N/A

170

Europe

Forced choice psychoacoustic task for the evaluation of modulation detection performance and selective auditory attention. (for both arm), Measurement of the pupil diameter for the evaluation of listening effort during speech perception, Non

Assistance Publique - Hôpitaux de Paris

Sensorineural Hearing Loss

06/24

PupillOM, NCT05586555: A Monocentric Study Evaluating Pupillometry as an Objective Measurement for CI Fittings

Terminated

N/A

Europe

Pupillometry (Eve-tracking measurements)

Oticon Medical

Hearing Loss, Sensorineural, Hearing Loss, Bilateral, Cochlear Hearing Loss, Hearing Loss, Cochlear

11/23

SURDICOG, NCT05149742: Deafness and Cognition in Middle-aged Adults

Recruiting

N/A

180

Europe

Cognitive and audiometry evaluation

Assistance Publique - HÃ´pitaux de Paris

Mild Cognitive Impairment in Middle-aged Adults

11/25

Light4Deaf, NCT04665726: Natural History Study of Usher Syndrome ( )

Recruiting

N/A

400

Europe

Centre Hospitalier National d'Ophtalmologie des Quinze-Vingts, Assistance Publique - HÃ´pitaux de Paris

Usher Syndromes

06/22

06/27

CIQoL, NCT05709431: A Study Evaluating the French Version of the -35 Quality of Life Questionnaire in Adult Cochlear Implant Use.

Recruiting

N/A

Europe

Questionnaire CIQoL-35

Oticon Medical

PROM, Cochlear Hearing Loss, Hearing Loss, Quality of Life

12/23

Bauer, Andrea

CALM-CSU, NCT06077773: Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of EP262 in Subjects With Chronic Spontaneous Urticaria

Recruiting

114

Europe, Canada, US

Oral EP262, Placebo

Escient Pharmaceuticals, Inc

Chronic Spontaneous Urticaria

01/25

02/25

CALM-CIndU, NCT06050928: Phase 1b, Open-Label Study to Evaluate the Safety, Tolerability, and Pharmacodynamics of EP262 in Subjects With Chronic Inducible Urticaria

Recruiting

Europe, Canada, US

Oral EP262

Escient Pharmaceuticals, Inc

Chronic Inducible Urticaria

09/24

11/24

NCT03002415: The Effect of Water Intake on the State of Hydration and Renal Function in Elderly Patients

Active, not recruiting

N/A

100

RoW

Guided water intake, Placebo - free demand water intake

Hospital de Clinicas de Porto Alegre

Renal Function Disorder

12/21

NCT01034969: Firazyr® Patient Registry (Icatibant Outcome Survey - IOS)

Recruiting

N/A

3000

Europe, RoW

Shire, Takeda Development Center Americas, Inc.

Hereditary Angioedema (HAE)

01/27

Osz, Mike

BMAD TX, NCT04096040: Benefits of Microcor in Ambulatory Decompensated Heart Failure

Completed

N/A

266

Europe, US

μCor

Zoll Medical Corporation

Heart Failure

06/23

10/23

ACAB, NCT04292405: Accuracy of Cardiac Acoustic Biomarkers Recorded by the Wearable Cardioverter Defibrillator

Recruiting

N/A

Wearable Cardioverter Defibrillator, AUDICOR AM

Zoll Medical Corporation

Heart Failure

03/24

05/24

Marquardt, Lars

Find-AF2, NCT04371055: Intensive Rhythm Monitoring to Decrease Ischemic Stroke and Systemic Embolism - the Find-AF 2 Study

Recruiting

N/A

5200

Europe

7-day Holter ECG, Implantable cardiac monitor, Standard of care

University of Leipzig, Johannes Gutenberg University Mainz

Ischemic Stroke, Atrial Fibrillation

06/26

12/26

Müller-Vahl, Kirsten

D1AMOND, NCT05615220: Ecopipam Tablets to Study Tourette's Disorder in Children, Adolescents and Adults

Recruiting

196

Europe, Canada, US, RoW

Ecopipam Hydrochloride

Emalex Biosciences Inc.

Tourette Disorder

12/24

NCT05126888: SCI-110 in the Treatment of Tourette Syndrome

Not yet recruiting

164

Europe, US, RoW

SCI-110, Placebo

SciSparc

Tourette Syndrome

08/25

12/25

Uebel, Peter

NCT05507216: ABTECT-2 - ABX464 Treatment Evaluation for Ulcerative Colitis Therapy -2

Recruiting

612

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

12/24

02/25

NCT05535946: ABTECT - Maintenance

Recruiting

1050

Europe, Canada, Japan, US, RoW

ABX464, Obefazimod, Placebo

Abivax S.A.

Ulcerative Colitis

01/26

06/26

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

Haverich, Axel

NCT03293264: Exercise Training on Metabolic Syndrome Severity in Employees

Completed

N/A

314

Europe

Exercise training group

Hannover Medical School, Volkswagen AG

Metabolic Syndrome

12/22

07/23

PAPA-ARTiS, NCT03434314 / 2018-000142-18: Paraplegia Prevention in Aortic Aneurysm Repair by Thoracoabdominal Staging

Active, not recruiting

N/A

500

Europe

Minimally-Invasive Segmental Artery Coil-Embolization

University of Leipzig, European Commission, German Research Foundation, Universidad de Granada, European Clinical Research Infrastructure Network, Modus Research and Innovation Limited, Rigshospitalet, Denmark, European Society of Cardiology, Baylor College of Medicine, University of Pennsylvania

Aortic Aneurysm, Thoracoabdominal

06/25

Monteleone, Giovanni

LUCENT-URGE, NCT05767021: A Study of Mirikizumab (LY3074828) in Participants With Moderately to Severely Active Ulcerative Colitis

Recruiting

160

Europe, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis, Ulcerative Colitis Chronic

12/24

03/25

LUCENT-3, NCT03519945 / 2017-004092-31: A Study to Evaluate the Long-Term Efficacy and Safety of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 3)

Jan 2022 - Mar 2022 : Data from LUCENT 3 trial for moderate-to-severe ulcerative colitis

Recruiting

1063

Europe, Canada, Japan, US, RoW

Mirikizumab, LY3074828

Eli Lilly and Company

Ulcerative Colitis

07/26

12/27

NCT06233461: A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Recruiting

268

Europe, Canada, Japan, US, RoW

TAK-279, Placebo

Takeda

Crohn's Disease

09/26

07/27

Welte, Tobias

HERO-19, NCT04542408: Hamburg Edoxaban for Anticoagulation in COVID-19 Study

Completed

140

Europe

Anticoagulation Agents (Edoxaban and/or high dose LMWH), Low dose Low molecular weight heparin or Placebo

Universitätsklinikum Hamburg-Eppendorf

Covid19

09/22

01/23

TRICOVID, NCT05531149 / 2022-000736-37: Efficacy and Safety of Trimodulin (BT588) in Subjects With CAP Including COVID-19 Pneumonia

Recruiting

390

Europe, RoW

Trimodulin, BT588, Placebo (human albumin 1%)

Biotest

Respiratory Infection, Pneumonia, Community-acquired Pneumonia, Acute Respiratory Distress Syndrome, COVID-19, Viral Pneumonia, Bacterial Pneumonia, Fungal Pneumonia

08/25

REPAVID-22, NCT05254990 / 2021-006951-32: Reparixin add-on Therapy to Std Care to Limit Progression in Pts With COVID19 & Other Community Acquired Pneumonia

Recruiting

526

Europe, US, RoW

Reparixin, Repertaxin L-lysine salt, Placebo, Matched placebo

Dompé Farmaceutici S.p.A

Infectious Pneumonia, Severe COVID-19

09/24

10/24

ESsCAPE, NCT05722938: Efficacy and Safety of Trimodulin (BT588) in Subjects With Severe Community-acquired Pneumonia (sCAP)

Recruiting

590

Europe, US, RoW

Trimodulin, BT588, Placebo (human albumin 1%)

Biotest

Community-acquired Pneumonia

02/25

04/25

NIMBLE, NCT04718389 / 2020-003612-28: A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype

Nov 2023 - Dec 2023 : Acceptance of regulatory submission in China for chronic rhinosinusitis with nasal polyps

Recruiting

1700

Europe, Canada, Japan, US, RoW

GSK3511294 (Depemokimab), Mepolizumab, Benralizumab, Placebo, Standard of care (SoC), Pre-filled Syringes (PFS)

GlaxoSmithKline, Iqvia Pty Ltd

Asthma

09/25

NCT04575064: An International Randomized Trial of Additional Treatments for COVID-19 in Hospitalized Patients Who Are All Receiving the Local Standard of Care - WHO-SOLIDARITY-GERMANY

Active, not recruiting

2/3

400

Europe

Standard of Care (SoC), Remdesivir

Professor Dr. Bernd Mühlbauer, Dept. of Statistics and Medical Biometry, University of Bremen, INSERM (Institut national de la santé et de la recherche médicale), Paris, France, World Health Organization (WHO), R&D Blueprint, Geneva, Switzerland

SARS-CoV-2 Infection, COVID-19, Moderate and Severe COVID-19

03/22

11/22

AGNES-19, NCT05156671: Adrecizumab (HAM8101) to Improve Prognosis and Outcomes in COVID-19 Trial

Terminated

Europe

Adrecizumab (HAM 8101), Placebo, Saline

Universitätsklinikum Hamburg-Eppendorf

COVID-19

08/23

11/23

TETRIS, NCT04657211: Triple Therapy in Chronic Obstructive Pulmonary Disease (COPD) Participants

Recruiting

N/A

2050

Europe

prospective observational cohort study

GlaxoSmithKline

Pulmonary Disease, Chronic Obstructive

04/24

TRIBE, NCT05652439: PASS to Assess Cardiovascular and Cerebrovascular Events in COPD Patients Initiating Fixed Triple Therapy (DPI or pMDI)

Recruiting

N/A

25000

Europe

Observational retrospective data collection, No treatment given

Chiesi Farmaceutici S.p.A.

Chronic Obstructive Pulmonary Disease

08/26

Mall, Marcus A

NCT04895332: BPOI (Berlin Pediatric Oxygenation Index) - A New Predictor for Imminent Failure of HFNC in Children Avoiding Delayed NIV or Intubation

Withdrawn

N/A

220

Charite University, Berlin, Germany

Respiratory Failure (Pediatric Patients)

12/21

TRACK-CF, NCT02270476: Longitudinal Observational Study on the Course of Cystic Fibrosis Lung Disease in Patients Following Newborn Screening

Recruiting

N/A

200

Europe

Heidelberg University, German Center for Lung Research

Cystic Fibrosis Lung Disease

12/30

Wedemeyer, Heiner

D-LIVR, NCT03719313 / 2018-003167-54: Study of the Efficacy and Safety of Lonafarnib / Ritonavir With and Without Pegylated Interferon -Alfa-2a

Completed

407

Europe, Canada, US, RoW

Lonafarnib, EBP994, Sarasar, LNF, Ritonavir, Norvir, RTV, PEG IFN-alfa-2a, Pegasys, pegylated interferon-alfa, Placebo Lonafarnib, Placebo Ritonavir

Eiger BioPharmaceuticals

Hepatitis Delta Virus

10/22

03/23

LIMT-2, NCT05070364: Phase 3 Study to Evaluate the Efficacy and Safety of Peginterferon Lambda for 48 Weeks in Patients With Chronic HDV

Active, not recruiting

150

Europe, US, RoW

Peginterferon Lambda-1a, Lambda, Peginterferon Lambda, Pegylated Interferon Lambda

Eiger BioPharmaceuticals

Hepatitis Delta Virus

06/24

01/25

B-Well 2, NCT05630820 / 2022-002268-53: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B

Active, not recruiting

859

Europe, Canada, Japan, US, RoW

Bepirovirsen, Placebo

GlaxoSmithKline, GlaxoSmithKline Research & Development Limited

Chronic Hepatitis B, Hepatitis B, Chronic

11/25

05/26

NCT05677971: Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein

Recruiting

160

Europe, Canada, US, RoW

Fazirsiran Injection, TAK-999, ARO-AAT, ADS-001, Placebo, Sodium chloride

Takeda, Takeda Development Center Americas, Inc.

Alpha1-Antitrypsin Deficiency

03/27

03/29

NCT04595825: CM-101 in PSC Patients -The SPRING Study

Active, not recruiting

Europe, US, RoW

Anti-human CCL24 monoclonal antibody (CM-101), Placebo

ChemomAb Ltd.

Primary Sclerosing Cholangitis

09/24

09/25

VISTAS, NCT04663308: A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Sclerosing Cholangitis (PSC)

Recruiting

200

Europe, Canada, US, RoW

Volixibat, SHP626, Placebo

Mirum Pharmaceuticals, Inc.

Primary Sclerosing Cholangitis

09/25

12/25

HBIG, NCT05345990: Treatment of Patients With Chronic Hepatitis B With Hepatitis B Immunoglobulins

Recruiting

Europe

Human hepatitis B Immunoglobulin (Hepatect®CP/Zutectra®)

Hannover Medical School, Biotest

Chronic Hepatitis B

11/24

05/25

HDV750, NCT06160635: D-SOLVE Cohorts (Cohort A and B)

Recruiting

N/A

750

Europe

Hannover Medical School, Karolinska University Hospital, Karolinska Institutet, Helmholtz Centre for Infection Research, Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico, National Institute of Infectious Diseases Matei Bals

HDV, HDV Infection, Chronic Liver Disease

09/26

NCT05239858: International Wilson's Disease Patient Registry (iWilson Registry)

Recruiting

N/A

500

Europe, RoW

Orphalan, Ergomed

Wilson's Disease

12/27

Schrappe, Martin

AIEOP-BFM ALL 2017, NCT03643276 / 2016-001935-12: Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia -

Recruiting

5000

Europe, RoW

Blinatumomab, Bortezomib, Cyclophosphamide, Cytarabine, Daunorubicin, Myocet, Dexamethasone, Doxorubicin, Etoposide, Fludarabine Phosphate, Ifosfamide, 6-Mercaptopurine, Methotrexate, Pegaspargase, Prednisolone, Prednisone, Tioguanin, Vincristine, Vindesine, Erwinase

Martin Schrappe, Deutsche Krebshilfe e.V., Bonn (Germany)

Acute Lymphoblastic Leukemia, Pediatric

07/28

Maecker-Kolhoff, Britta

TRACE, NCT04832607 / 2018-000853-29: Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections

Recruiting

149

Europe

Multivirus (CMV, EBV, AdV)-specific T cells

Prof. Tobias Feuchtinger, European Commission, Simbec-Orion Group Ltd, Merthyr Tydfil, UK, Miltenyi Biotec B.V. & Co. KG, Bergisch Gladbach, Germany, Leiden University Medical Center, LUMC, Leiden, The Netherlands, Centre Hospitalier Universitaire de Nancy, CHU, Vandoeuvre-Lès-Nancy, France, Ghent University Hospital, UZG, Ghent, Belgium, Ospedale Pediatrico Bambino Gesù, OPBG, Rome, Italy, Newcastle University, UNEW, Newcastle, UK, Vall d'Hebron Institute of Oncology (VHIO) and Banc de Sang I Teixits (BST), Barcelona, Spain

AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications

06/24

12/24

NCT05319353 / 2021-004279-15: A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, and Antiviral Activity of Maribavir for the Treatment of Children and Teenage Transplant Recipients With CMV Infection

Recruiting

Europe, Japan, US, RoW

Maribavir, TAK-620

Takeda, Takeda Development Center Americas, Inc.

Cytomegalovirus (CMV)

11/26

Prasse, Antje

NCT05130970 / 2021-003162-12: CSL312 Safety, Pharmacokinetics, and Pharmacodynamics in Idiopathic Pulmonary Fibrosis

Completed

Europe, Canada, US, RoW

CSL312, Factor XIIa antagonist monoclonal antibody, Garadacimab, Placebo

CSL Behring

Idiopathic Pulmonary Fibrosis

01/24

NCT06472362: Chest CT Biomarkers as Prognostic Predictors in SSc-ILD

Not yet recruiting

N/A

1000

Europe

HRCT biomarkers

Royal Brompton & Harefield NHS Foundation Trust, Imperial College London, Royal Free and University College Medical School, The Leeds Teaching Hospitals NHS Trust, Hannover Medical School, University of Siena, Università Politecnica delle Marche, Azienda Ospedaliero Universitaria di Sassari, Bichat Hospital

Systemic Sclerosis

06/25

03/26

Petri, Susanne

COURAGE-ALS, NCT04944784 / 2020-004040-29: A Study to Evaluate the Efficacy and Safety of Reldesemtiv in Patients With Amyotrophic Lateral Sclerosis (ALS)

Terminated

486

Europe, Canada, US, RoW

Reldesemtiv, Placebo

Cytokinetics

Amyotrophic Lateral Sclerosis

07/23

ATLAS, NCT04856982 / 2020-004590-51: A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation

Recruiting

150

Europe, Canada, Japan, US, RoW

Tofersen, BIIB067, QALSODY, Placebo

Biogen

Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation

08/27

NCT05039099: A Study to Evaluate, Safety, Tolerability, Pharmacodynamic (PD) Markers and Pharmacokinetics (PK) of AP-101 in Participants With Amyotrophic Lateral Sclerosis (ALS)

Active, not recruiting

Europe, Canada, US, RoW

AP-101, Placebo

AL-S Pharma

Amyotrophic Lateral Sclerosis

12/24

10/25

NfL-ALS, NCT06201650: Neurofilament Light Chain in Amyotrophic Lateral Sclerosis

Recruiting

N/A

3000

Europe

Neurofilament light chain

Charite University, Berlin, Germany, Boris Canessa ALS Stiftung

Amyotrophic Lateral Sclerosis, Motor Neuron Disease

12/24

LIPCAL-ALS II, NCT06280079: Ultra-high-caloric, Fatty Diet in ALS

Not yet recruiting

N/A

392

Europe

Ultra-high-caloric fatty diet, Placebo

University of Ulm

Amyotrophic Lateral Sclerosis

05/27

Thol, Felicitas

NCT03897127: Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics

Recruiting

882

Europe

Cytarabine, Daunorubicin, CPX-351

University of Ulm, Jazz Pharmaceuticals

Acute Myeloid Leukemia

03/24

AMLSG BiO, NCT01252485: Registry Study on Patient Characteristics, Biological Disease Profile and Clinical Outcome in Acute Myeloid Leukemia and Related Neoplasms, and Higher Risk Myelodysplastic Syndrome - The Biology and Outcome (BiO)-Project

Recruiting

N/A

Europe

University of Ulm

Acute Myeloid Leukemia (AML), Higher Risk Myelodysplastic Syndromes (MDS With Excess Blasts 2)

Wedemeyer, Hans H

NCT04594694 / 2018-002575-17: Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC

Active, not recruiting

Europe, RoW

Obeticholic acid, Bezafibrate 200 MG, OCA Placebo, Bezafibrate 200 mg Placebo, Bezafibrate 400 MG, Bezafibrate 400 mg Placebo, OCA, Bezafibrate

Intercept Pharmaceuticals

Primary Biliary Cholangitis

10/25

12/25

BISCIT, NCT05396755: Biliary Interventions in Critically Ill Patients With Secondary Sclerosing Cholangitis

Terminated

N/A

Europe

Endoscopic retrograde cholangiography (ERC)

Hannover Medical School, German Research Foundation

Secondary Sclerosing Cholangitis

09/23

Schwerk, Nicolaus

NCT02852928: European Management Platform for Childhood Interstitial Lung Diseases - chILD-EU Register and Biobank

Recruiting

N/A

1000

Europe, RoW

Matthias Griese

Lung Diseases, Interstitial, Pulmonary Alveolar Proteinosis, Pulmonary Eosinophilia, Pulmonary Fibrosis, Respiratory Distress Syndrome, Newborn, Child

12/28

12/29

David, Sascha

REMAP-CAP, NCT02735707 / 2015-002340-14: Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting

20000

Europe, Canada, Japan, US, RoW

Ceftriaxone, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam, Ceftaroline, Amoxicillin-clavulanate, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, IFN-β1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, acetylsalicylic acid, P2Y12 inhibitor, Clopidogrel, Prasugrel, Ticagrelor, No simvastatin, Simvastatin, Placebo, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Ramipril, Lisinopril, Perindopril, Enalapril, Trandolapril, Captopril, Angiotensin Receptor Blockers, Losartan, Valsartan, Candesartan, Irbesartan, Telmisartan, Olmesartan, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Paxlovid, Remdesivir, Nirmatrelvir/ritonavir + remdesivir

UMC Utrecht, Australian and New Zealand Intensive Care Research Centre, Medical Research Institute of New Zealand, Unity Health, Berry Consultants, Global Coalition for Adaptive Research, University of Pittsburgh Medical Center, Intensive Care National Audit & Research Centre, St. Marianna University School of Medicine, National Intensive Care Surveillance MORU, National University Hospital, Singapore

Community-acquired Pneumonia, Influenza, COVID-19

02/26

02/28

CYTORELEASE, NCT04048434: Extracorporeal Cytokine Adsorption as Additive Treatment of CAR-T Associated Cytokine Release Syndrome (CRS)

Recruiting

N/A

Europe

Cytosorb

Hannover Medical School, CytoSorbents, Inc

Cytokine Release Syndrome, CAR-T

09/23

09/24

(RESTORE), NCT06258291: First in Human Trial to Assess the Safety of HemoSystem REBOOT in Patients With Sepsis-induced Immunosuppression

Not yet recruiting

N/A

Europe

Hemosystem REBOOT, extracorporeal blood purification

hemotune AG

Septic Shock

07/25

10/25

NUC-CAP, NCT05647096: Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating cfDNA/NETs in Subjects With Sepsis

Not yet recruiting

N/A

Europe

NucleoCapture device

Santersus AG, ISS AG

Sepsis, Respiratory Failure

05/26

EXCHANGE-2, NCT05726825: Efficacy of add-on Plasma Exchange as an Adjunctive Strategy Against Septic Shock

Not yet recruiting

N/A

274

Europe

Therapeutic Plasma Exchange (TPE)

Hannover Medical School

Septic Shock

08/26

01/27

NCT04853953: Cerebral Bleeding in COVID-19 ARDS Patients on Veno-venous ECMO

Not yet recruiting

N/A

400

Incidence of bleeding complications in ARDS patients on veno-venous ECMO

University of Zurich, Hannover Medical School, University Hospital, Bonn

Acute Respiratory Distress Syndrome, Extracorporeal Membrane Oxygenation Complication, Corona Virus Infection

07/21

12/21

Chen, Kai

TOP-CABG, NCT05380063: Ticagrelor-based De-escalation of Dual Antiplatelet Therapy After Coronary Artery Bypass Grafting

Recruiting

2300

RoW

De-escalated Dual Antiplatelet Therapy, De-escalation, Dual Antiplatelet Therapy

China National Center for Cardiovascular Diseases

Coronary Artery Disease, Coronary Artery Bypass Grafting, Dual Antiplatelet Therapy, Bleeding, Myocardial Infarction, Myocardial Ischemia, Angina Pectoris

12/24

12/25

OFFER, NCT04536558: Olanzapine Plus Fosaprepitant Standard Antiemetic Therapy in the Prevention of Chemotherapy-induced Nausea and Vomiting in Patients Receiving High Emetic Risk Multi-day Chemotherapy: a Multicenter, Randomized, Double-blind, Placebo-controlled, Phase 3 Study

Not yet recruiting

352

RoW

olanzapine plus fosaprepitant-based triple regimen, placebo plus fosaprepitant-based triple regimen

Sun Yat-sen University, Jiangsu Hansoh Pharmaceutical Co., Ltd.

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

02/21

03/21

NCT04714190: A Study of RC48-ADC in Local Advanced or Metastatic Gastric Cancer With the HER2-Overexpression

Recruiting

351

RoW

RC48-ADC, Recombinant Humanized anti-HER2 Monoclonal Antibody-MMAE Conjugate For Injection, Paclitaxel injection, Taxol, Irinotecan Hydrochloride Injection, CAMPTO, Apatinib Mesylate Tablets, Aitan

RemeGen Co., Ltd.

Gastric Cancer, HER2 Overexpressing Gastric Carcinoma

12/24

06/25

TQB2450-III-05, NCT04325763: A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)

Recruiting

315

RoW

TQB2450, Anlotinib, TQB2450(blank), Anlotinib(blank)

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Stage III Non-small-cell Lung Cancer

12/22

03/25

MOUNTAINEER-03, NCT05253651 / 2021-002672-40: A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Recruiting

400

Europe, Canada, Japan, US, RoW

tucatinib, TUKYSA, ONT-380, ARRY-380, trastuzumab, Herceptin, bevacizumab, Avastin, cetuximab, Erbitux, oxaliplatin, leucovorin, levoleucovorin, fluorouracil

Seagen Inc., Merck Sharp & Dohme LLC

Colorectal Neoplasms

08/25

04/28

NCT04872985: Pyrotinib in Combination With Neoadjuvant Chemotherapy in HR+/HER2-, HER4 High Expression Breast Cancer Patients: A Phase II Trial

Recruiting

140

RoW

Pyrotinib, Epirubicin, E, Doxorubicin Hydrochloride Liposome Injection, A, Cyclophosphamide, C, Docetaxel, T, Nab paclitaxel, Placebo

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Jiangsu HengRui Medicine Co., Ltd.

Breast Cancer, Hormone-receptor Positive Breast Cancer

12/23

12/28

NCT05729399: Clinical Study of Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for Advanced Solid Tumors

Recruiting

RoW

GT201

Grit Biotechnology

Solid Tumor

05/25

NCT04003558: Deep Learning Algorithms for Prediction of Lymph Node Metastasis and Prognosis in Breast Cancer MRI Radiomics (RBC-01)

Recruiting

N/A

1500

RoW

No interventions

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Tungwah Hospital of Sun Yat-Sen University, Shunde Hospital of Southern Medical University, Zhongshan Ophthalmic Center, Sun Yat-sen University

Breast Neoplasm Female, Early-stage Breast Cancer, Radiomics, Axillary Lymph Node, Survival, Prosthesis

05/20

01/25

RBC-02, NCT04004559: MRI Radiomics Assessing Neoadjuvant Chemotherapy in Breast Cancer to Predict Lymph Node Metastasis and Prognosis

Recruiting

N/A

600

RoW

No interventions

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Sun Yat-sen University, Tungwah Hospital of Sun Yat-Sen University

Invasive Breast Cancer, Neoadjuvant Chemotherapy, Radiomics, Axillary Lymph Node, Prognosis

10/20

05/25

NCT04004494: 3D Reconstruction in Video-assisted Thoracoscopic Surgery (VATS) Segmentectomy

Completed

N/A

191

RoW

3D reconstruction

Ruijin Hospital, Union hospital of Fujian Medical University, Guangdong Provincial People's Hospital

Segmentectomy

10/23

12/23

PREPOSE, NCT03010033: Effect of Pulmonary Rehabilitation on Perioperative Outcomes in Smoker Patients With Lung Cancer

Recruiting

N/A

200

RoW

pulmonary rehabilitation

Ruijin Hospital

Pulmonary Neoplasm

09/22

12/22

HFpEF-BB, NCT05174351: Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction

Recruiting

N/A

beta blocker discontinuation

UConn Health

Heart Failure With Preserved Ejection Fraction

11/22

NCT06425874: The Impact of Socioeconomic Determinants on the Patient Reported Outcomes in Young Breast Cancer Patients After Breast Surgery

Recruiting

N/A

1000

RoW

Breast-conserving surgery, Mastectomy, Mastectomy with reconstruction

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

Breast Cancer, Surgery, Quality of Life

12/35

NCT05638269: A Multicentre Study on Features of the Gut Microbiota of Patients With Critical Chronic Diseases in China

Recruiting

N/A

12000

RoW

no intervention

Zhujiang Hospital, National Natural Science Foundation of China

Essential Hypertension, Liver Cancer, Nasopharyngeal Cancer, Pancreatic Cancer, Lung Cancer, Chronic Kidney Diseases, Acute Coronary Syndrome, Epilepsy, Gastric Cancer, Primary Aldosteronism, Subclinical hypothyroÃ¯dism

12/24

12/25

Witte, Torsten

TOPAZ-2, NCT04961567 / 2020-005776-35: A Study to Learn About the Safety of Litifilimab (BIIB059) Injections and Whether They Can Improve Symptoms of Adult Participants Who Have Systemic Lupus Erythematosus

Recruiting

540

Europe, Canada, Japan, US, RoW

Litifilimab, BIIB059, Placebo

Biogen

Lupus Erythematosus, Systemic

09/25

03/26

Lupus-Best, NCT05714930: LUPUS-BEST - Treat-to-target in Systemic Lupus Erythematosus

Recruiting

N/A

606

Europe

Treat-to-target as a new treatment concept

Heinrich-Heine University, Duesseldorf, University Hospital Heidelberg, German Diabetes-Center, Leibniz-Institut in Düsseldorf, Lupus Erythematodes-Selbsthilfegemeinschaft e.V.

Systemic Lupus Erythematosus

04/26

09/26

Park-Simon, Tjoung-Won

HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Recruiting

650

Europe, Canada, Japan, US, RoW

Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo

Seagen Inc., Merck Sharp & Dohme LLC

HER2 Positive Breast Cancer

10/24

06/27

ZEST, NCT04915755 / 2020-003973-23: Efficacy and Safety Comparison of Niraparib to Placebo in Participants With Human Epidermal Growth Factor 2 Negative (HER2-) Breast Cancer Susceptibility Gene Mutation (BRCAmut) or Triple-Negative Breast Cancer (TNBC) With Molecular Disease

Jan 2025 - Dec 2025: Pivotal data from ZEST trial for HER2-negative BRCA-mutated or triple-negative breast cancer

Active, not recruiting

Europe, Canada, Japan, US, RoW

Niraparib, Placebo

GlaxoSmithKline

Neoplasms, Breast

03/25

08/29

ADAPTlate, NCT04565054 / 2019-001488-60: Adjuvant Therapy With Abemaciclib + SOC ET vs. SOC ET in Clinical or Genomic High Risk, HR+/HER2- EBC

Recruiting

1260

Europe

Abemaciclib 50 MG; 150mg 1-0-1 per os, Verzenios

West German Study Group, Eli Lilly and Company, Genomic Health®, Inc.

Breast Cancer Female

08/26

03/28

ADAPTcycle, NCT04055493: Adj. Marker-adjusted Personalized Therapy Comparing ET+Ribociclib vs Chemotherapy in Intermediate Risk, HR+/HER2- EBC

Recruiting

1670

Europe

Ribociclib 200Mg Oral Tablet, Kisqali

West German Study Group, Novartis, Genomic Health®, Inc.

Breast Cancer Female

07/27

MIROVA, NCT04274426: Mirvetuximab Soravtansine (IMGN853), in Folate Receptor Alpha (FRα) High Recurrent Ovarian Cancer

Recruiting

136

Europe

Carboplatin, Pegylated liposomal doxorubicin (PLD), Gemcitabine, Paclitaxel, Mirvetuximab Soravtansine

AGO Research GmbH

Recurrent Epithelial Ovarian, Fallopian or Peritoneal Carcinoma

12/25

12/26

Diaz, Roberto

HERIZON-GEA-01, NCT05152147 / 2021-000296-36: A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in Patients With HER2-positive Advanced or Metastatic Gastric and Esophageal Cancers

Recruiting

918

Europe, Canada, Japan, RoW

Zanidatamab, ZW25, JZP598, Tislelizumab, Trastuzumab, Herceptin®, Capecitabine, Oxaliplatin, Cisplatin, 5-Fluorouracil

Jazz Pharmaceuticals, BeiGene, Ltd.

Gastric Neoplasms, Gastroesophageal Adenocarcinoma, Esophageal Adenocarcinoma

12/24

07/25

TAILOR RT, NCT03488693: Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast Cancer

Recruiting

2140

Canada, US

Radiation, No Radiation

Canadian Cancer Trials Group, Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, NRG Oncology, SWOG Cancer Research Network

Breast Cancer

09/27

12/27

EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting

6000

Europe, Canada, Japan, US, RoW

Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane

Eli Lilly and Company

Breast Neoplasms

10/27

03/32

HERO, NCT05705401: Testing Radiation and HER2-targeted Therapy Versus HER2-targeted Therapy Alone for Low-risk HER2-positive Breast Cancer

Recruiting

1300

Standard of Care Adjuvant Breast Radiation, Standard of Care HER2-targeted Therapy Without Adjuvant Breast Radiation

NRG Oncology, National Cancer Institute (NCI), Alliance for Clinical Trials in Oncology, Eastern Cooperative Oncology Group, SWOG Cancer Research Network

HER2-positive Breast Cancer

02/34

02/37

OpcemISA, NCT03669718 / 2018-000789-13: A Randomized Phase 2 Study of Cemiplimab ± ISA101b in HPV16-Positive OPC

Active, not recruiting

194

Europe, US, RoW

ISA101b, Cemiplimab, Placebo

ISA Pharmaceuticals, Regeneron Pharmaceuticals

Squamous Cell Carcinoma of the Oropharynx, HPV16 Positive

09/24

06/25

NCT05115474: Study of Screening Brain MRIs in Stage IV Breast Cancer

Recruiting

100

Magnetic Resonance Imaging, MRI

H. Lee Moffitt Cancer Center and Research Institute, Florida Breast Cancer Foundation

Triple Negative Breast Cancer, HER2-positive Breast Cancer, Hormone Receptor-positive Breast Cancer

08/24

NCT05528133: Genomically Guided Radiation Therapy in the Management of Triple Negative Breast Cancer

Recruiting

Genomically Guided Radiation Therapy

H. Lee Moffitt Cancer Center and Research Institute

Triple Negative Breast Cancer

01/26

01/27

Kahl, Kai

SIMCODE, NCT04301271: Simvastatin add-on Treatment to Standard Antidepressant Therapy in Patients With Comorbid Obesity and Major Depression

Active, not recruiting

161

Europe

Simvastatin 40mg, Zocor, C10AA01, Placebo oral tablet

Charite University, Berlin, Germany, NeuroCure Clinical Research Center, Charite, Berlin, University Medical Center Goettingen

Depressive Disorder, Major, Obesity

02/25

ChangePDD, NCT04996433: A Comparison of Two Psychotherapy Programs in Persistently Depressed Treatment-Resistant Inpatients

Recruiting

N/A

396

Europe

inpatient CBASP individual therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient individual therapy, inpatient CBASP group therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient group therapy, inpatient CBASP nurse contact, Cognitive Behavioral Analysis System of Psychotherapy - inpatient nurse contact, inpatient CBASP exercise therapy, Cognitive Behavioral Analysis System of Psychotherapy - inpatient exercise therapy, outpatient CBASP group therapy, Cognitive Behavioral Analysis System of Psychotherapy - outpatient group therapy, inpatient BA individual therapy, Behavioral Activation - inpatient individual therapy, inpatient BA group therapy, Behavioral Activation - inpatient group therapy, inpatient BA nurse contact, Behavioral Activation - inpatient nurse contact, inpatient BA exercise therapy, Behavioral Activation - inpatient exercise therapy, outpatient BA group therapy, Behavioral Activation - outpatient group therapy, algorithm-based study medication, antidepressant medication

University of Greifswald, German Research Foundation, University of Kassel, University Medicine Greifswald, Charite University, Berlin, Germany, Hannover Medical School, University Hospital Lübeck, Philipps University Marburg Medical Center, Ludwig-Maximilians - University of Munich, University Hospital Tuebingen

Persistent Depressive Disorder, Treatment-resistant Depression

07/24

05/26

MECT-RESIST, NCT06456983: Maintenance ElectroConvulsive Therapy in Clozapine RESISTant Schizophrenia - the Trial

Not yet recruiting

N/A

140

Europe

maintenance electroconvulsive therapy (mECT)

Central Institute of Mental Health, Mannheim

Schizophrenia, Treatment Resistant Schizophrenia

07/27

07/28

Hoffmann, Oliver

CAPTOR-BC, NCT05452213: Comprehensive Analysis of Spatial, Temporal and Molecular Patterns of Ribociclib Efficacy and Resistance in Advanced Breast Cancer Patients

Recruiting

1000

Europe

Ribociclib

Institut fuer Frauengesundheit, AGO Breast Study Group e.V., Novartis Pharmaceuticals

Breast Cancer, Breast Neoplasms, Breast Neoplasm Female, Breast Cancer Female, HER2-negative Breast Cancer, Hormone Receptor-positive Breast Cancer, Advanced Breast Cancer

10/24

10/26



	Diseases Companies Products Productz Mechanisms of Action Sites